| scholarly article | Q13442814 |
| P356 | DOI | 10.1074/JBC.M002807200 |
| P698 | PubMed publication ID | 10816582 |
| P2093 | author name string | He B | |
| Wilson EM | |||
| Kemppainen JA | |||
| P433 | issue | 30 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ligand binding | Q61659151 |
| P304 | page(s) | 22986-22994 | |
| P577 | publication date | 2000-07-01 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor | |
| P478 | volume | 275 |
| Q47547733 | A Fragment of Adhesion Molecule L1 Binds to Nuclear Receptors to Regulate Synaptic Plasticity and Motor Coordination |
| Q36855802 | A common motif targets huntingtin and the androgen receptor to the proteasome |
| Q36078731 | A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes |
| Q24304373 | A direct beta-catenin-independent interaction between androgen receptor and T cell factor 4 |
| Q39166625 | A multi-parameter imaging assay identifies different stages of ligand-induced androgen receptor activation. |
| Q37210787 | A novel androgen receptor amino terminal region reveals two classes of amino/carboxyl interaction-deficient variants with divergent capacity to activate responsive sites in chromatin |
| Q24336995 | A novel function of caspase-8 in the regulation of androgen-receptor-driven gene expression |
| Q24338270 | A novel inducible transactivation domain in the androgen receptor: implications for PRK in prostate cancer |
| Q30748653 | ARA67/PAT1 functions as a repressor to suppress androgen receptor transactivation |
| Q39338812 | Allosteric conversation in the androgen receptor ligand-binding domain surfaces. |
| Q36681464 | Allosteric modulators of steroid hormone receptors: structural dynamics and gene regulation |
| Q34140002 | Alternative inhibition of androgen receptor signaling: peptidomimetic pyrimidines as direct androgen receptor/coactivator disruptors |
| Q38360677 | Amino acids 3-13 and amino acids in and flanking the 23FxxLF27 motif modulate the interaction between the N-terminal and ligand-binding domain of the androgen receptor |
| Q34285154 | An Interdomain Interaction of the Androgen Receptor Is Required for Its Aggregation and Toxicity in Spinal and Bulbar Muscular Atrophy |
| Q28258333 | An androgen receptor NH2-terminal conserved motif interacts with the COOH terminus of the Hsp70-interacting protein (CHIP) |
| Q39499483 | Analysis of interdomain interactions of the androgen receptor |
| Q92410955 | Androgen Receptor Dependence |
| Q29036974 | Androgen Receptor Exon 1 Mutation Causes Androgen Insensitivity by Creating Phosphorylation Site and Inhibiting Melanoma Antigen-A11 Activation of NH2- and Carboxyl-terminal Interaction-dependent Transactivation |
| Q90266952 | Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer |
| Q39227656 | Androgen Signaling in Prostate Cancer |
| Q24305403 | Androgen receptor auto-regulates its expression by a negative feedback loop through upregulation of IFI16 protein |
| Q46950377 | Androgen receptor genotyping in a large Australasian cohort with androgen insensitivity syndrome; identification of four novel mutations |
| Q24602861 | Androgen receptor molecular biology and potential targets in prostate cancer |
| Q33518450 | Androgen receptor mutations associated with androgen insensitivity syndrome: a high content analysis approach leading to personalized medicine |
| Q79964099 | Androgen receptor regulates nuclear trafficking and nuclear domain residency of corepressor HDAC7 in a ligand-dependent fashion |
| Q36237251 | Androgen receptor regulation by histone methyltransferase Suppressor of variegation 3-9 homolog 2 and Melanoma antigen-A11. |
| Q35868187 | Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation. |
| Q35183663 | Androgen receptor signaling in prostate cancer development and progression |
| Q38780007 | Androgen receptor-related diseases: what do we know? |
| Q36063723 | Androgen receptor: structure, role in prostate cancer and drug discovery |
| Q37732971 | Androgen regulation of gene expression |
| Q55357541 | Androgen-Induced Immunosuppression. |
| Q44410588 | Anti-androgenic properties of Compound A, an analog of a non-steroidal plant compound |
| Q44588655 | Attenuation of androgen receptor-dependent transcription by the serine/threonine kinase Pim-1. |
| Q33292178 | Beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription |
| Q38076345 | Beyond the ligand-binding pocket: targeting alternate sites in nuclear receptors. |
| Q42322498 | Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer |
| Q36386200 | Characterization of a novel androgen receptor (AR) coregulator RIPK1 and related chemicals that suppress AR-mediated prostate cancer growth via peptide and chemical screening |
| Q28543404 | Characterization of niphatenones that inhibit androgen receptor N-terminal domain |
| Q42680540 | Cloning and expression analysis of androgen receptor gene in chicken embryogenesis |
| Q36174638 | Co-activator candidate interactions for orphan nuclear receptor NR2E1. |
| Q27650466 | Communication between the ERRalpha homodimer interface and the PGC-1alpha binding surface via the helix 8-9 loop |
| Q24683283 | Compartmentalization of androgen receptor protein-protein interactions in living cells |
| Q43918738 | Conformational analysis of the androgen receptor amino-terminal domain involved in transactivation. Influence of structure-stabilizing solutes and protein-protein interactions |
| Q34775572 | Constitutive activity of the androgen receptor |
| Q34165500 | Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor |
| Q37691685 | Coregulator control of androgen receptor action by a novel nuclear receptor-binding motif |
| Q35858203 | Corepressor effect on androgen receptor activity varies with the length of the CAG encoded polyglutamine repeat and is dependent on receptor/corepressor ratio in prostate cancer cells. |
| Q36995628 | Crystallization and preliminary X-ray analysis of the human androgen receptor ligand-binding domain with a coactivator-like peptide and selective androgen receptor modulators. |
| Q27631345 | Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone |
| Q57108090 | Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer |
| Q34478869 | Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation |
| Q52584077 | Cyclin D3 action in androgen receptor regulation and prostate cancer. |
| Q40733079 | Dependence of selective gene activation on the androgen receptor NH2- and COOH-terminal interaction |
| Q36566706 | Development of a novel cell based androgen screening model |
| Q37169881 | Differential presentation of protein interaction surfaces on the androgen receptor defines the pharmacological actions of bound ligands. |
| Q37210875 | Diverse roles of androgen receptor (AR) domains in AR-mediated signaling |
| Q34137546 | Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer |
| Q24337271 | Dosage-sensitive sex reversal adrenal hypoplasia congenita critical region on the X chromosome, gene 1 (DAX1) (NR0B1) and small heterodimer partner (SHP) (NR0B2) form homodimers individually, as well as DAX1-SHP heterodimers |
| Q38359046 | Dual function of an amino-terminal amphipatic helix in androgen receptor-mediated transactivation through specific and nonspecific response elements |
| Q41115283 | EPI-001, A Compound Active against Castration-Resistant Prostate Cancer, Targets Transactivation Unit 5 of the Androgen Receptor |
| Q24550576 | Electrostatic modulation in steroid receptor recruitment of LXXLL and FXXLF motifs |
| Q40609407 | Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer |
| Q24652929 | Epidermal-growth-factor-dependent phosphorylation and ubiquitinylation of MAGE-11 regulates its interaction with the androgen receptor |
| Q37871071 | Essential functions of androgen signaling emerged through the developmental analysis of vertebrate sex characteristics |
| Q36210938 | Evidence for DNA-binding domain--ligand-binding domain communications in the androgen receptor |
| Q52637989 | Evolution of Melanoma Antigen-A11 (MAGEA11) During Primate Phylogeny. |
| Q37482979 | Evolutionary history and functional characterization of androgen receptor genes in jawed vertebrates. |
| Q34958051 | Filamin-A fragment localizes to the nucleus to regulate androgen receptor and coactivator functions |
| Q39906248 | FoxO1 mediates PTEN suppression of androgen receptor N- and C-terminal interactions and coactivator recruitment |
| Q35003769 | Functional screening of FxxLF-like peptide motifs identifies SMARCD1/BAF60a as an androgen receptor cofactor that modulates TMPRSS2 expression |
| Q29040033 | Gain in Transcriptional Activity by Primate-specific Coevolution of Melanoma Antigen-A11 and Its Interaction Site in Androgen Receptor |
| Q37239796 | Hormone control and expression of androgen receptor coregulator MAGE-11 in human endometrium during the window of receptivity to embryo implantation |
| Q92509338 | Hsp70 and Hsp40 inhibit an inter-domain interaction necessary for transcriptional activity in the androgen receptor |
| Q24607572 | Human checkpoint protein hRad9 functions as a negative coregulator to repress androgen receptor transactivation in prostate cancer cells |
| Q27659041 | Identification of SRC3/AIB1 as a Preferred Coactivator for Hormone-activated Androgen Receptor |
| Q24301596 | Identification of a new androgen receptor (AR) co-regulator BUD31 and related peptides to suppress wild-type and mutated AR-mediated prostate cancer growth via peptide screening and X-ray structure analysis |
| Q73483127 | Implications of a polyglutamine tract in the function of the human androgen receptor |
| Q37161795 | Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP. |
| Q24292392 | Inhibition of androgen receptor (AR) function by the reproductive orphan nuclear receptor DAX-1 |
| Q36312095 | Inhibition of androgen receptor by decoy molecules delays progression to castration-recurrent prostate cancer |
| Q43892365 | Inhibition of androgen receptor functions by gelsolin FxxFF peptide delivered by transfection, cell-penetrating peptides, and lentiviral infection |
| Q44366991 | Interdomain interactions in the mineralocorticoid receptor |
| Q73258493 | Ligand- and coactivator-mediated transactivation function (AF2) of the androgen receptor ligand-binding domain is inhibited by the cognate hinge region |
| Q40251128 | Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells |
| Q24681534 | Ligand-specific dynamics of the androgen receptor at its response element in living cells |
| Q43730398 | Mapping the unique activation function 3 in the progesterone B-receptor upstream segment. Two LXXLL motifs and a tryptophan residue are required for activity |
| Q37432393 | Mechanism of androgen receptor corepression by CKβBP2/CRIF1, a multifunctional transcription factor coregulator expressed in prostate cancer |
| Q46882539 | Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression. |
| Q33976024 | Mechanistic relationship between androgen receptor polyglutamine tract truncation and androgen-dependent transcriptional hyperactivity in prostate cancer cells |
| Q24556963 | Melanoma antigen gene protein MAGE-11 regulates androgen receptor function by modulating the interdomain interaction |
| Q35007914 | Melanoma antigen gene protein-A11 (MAGE-11) F-box links the androgen receptor NH2-terminal transactivation domain to p160 coactivators |
| Q34313140 | Melanoma antigen-A11 (MAGE-A11) enhances transcriptional activity by linking androgen receptor dimers |
| Q40614663 | Methods for detecting domain interactions in nuclear receptors |
| Q34700667 | Minor hypospadias: the "tip of the iceberg" of the partial androgen insensitivity syndrome |
| Q27646416 | Modulation of Androgen Receptor Activation Function 2 by Testosterone and Dihydrotestosterone |
| Q90711422 | Modulation of androgen receptor DNA binding activity through direct interaction with the ETS transcription factor ERG |
| Q24295257 | Modulation of human nuclear receptor LRH-1 activity by phospholipids and SHP |
| Q60015421 | Molecules targeting the androgen receptor (AR) signaling axis beyond the AR-Ligand binding domain |
| Q37737611 | Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer |
| Q35813270 | Multiple mechanisms of male-specific gene expression: lessons from the mouse sex-limited protein (Slp) gene |
| Q41466777 | Muscle-bound? A tissue-selective nonsteroidal androgen receptor modulator |
| Q36803788 | Natural disordered sequences in the amino terminal domain of nuclear receptors: lessons from the androgen and glucocorticoid receptors |
| Q40386419 | Neofunctionalization of Androgen Receptor by Gain-of-Function Mutations in Teleost Fish Lineage. |
| Q37899974 | Neurotoxic effects of androgens in spinal and bulbar muscular atrophy. |
| Q52659701 | New Opportunities for Targeting the Androgen Receptor in Prostate Cancer. |
| Q34338685 | Noncanonical mechanisms to regulate nuclear receptor signaling |
| Q83323002 | Novel FXXFF and FXXMF motifs in androgen receptor cofactors mediate high affinity and specific interactions with the ligand-binding domain |
| Q24608984 | Nuclear actin and actin-binding proteins in the regulation of transcription and gene expression |
| Q28138773 | Oct-1 preferentially interacts with androgen receptor in a DNA-dependent manner that facilitates recruitment of SRC-1 |
| Q27007098 | Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy |
| Q42006129 | Positive feedback loop mediated by protein phosphatase 1α mobilization of P-TEFb and basal CDK1 drives androgen receptor in prostate cancer |
| Q36139948 | Post-translational Down-regulation of Melanoma Antigen-A11 (MAGE-A11) by Human p14-ARF Tumor Suppressor |
| Q35223874 | Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone |
| Q30361988 | Preventing the Androgen Receptor N/C Interaction Delays Disease Onset in a Mouse Model of SBMA |
| Q36298532 | Primate-specific melanoma antigen-A11 regulates isoform-specific human progesterone receptor-B transactivation |
| Q34282690 | Progesterone receptor transcription and non-transcription signaling mechanisms |
| Q37112738 | Proto-oncogene activity of melanoma antigen-A11 (MAGE-A11) regulates retinoblastoma-related p107 and E2F1 proteins |
| Q44068352 | Pure antiandrogens disrupt the recruitment of coactivator GRIP1 to colocalize with androgen receptor in nuclei |
| Q36464850 | Receptor-interacting protein 140 is a repressor of the androgen receptor activity |
| Q24799399 | Recognition and accommodation at the androgen receptor coactivator binding interface |
| Q47310629 | Regulation of Androgen Receptor Activity by Transient Interactions of Its Transactivation Domain with General Transcription Regulators. |
| Q33962627 | Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. |
| Q24793292 | Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation |
| Q39439753 | Regulation of androgen receptor-dependent transcription by coactivator MED1 is mediated through a newly discovered noncanonical binding motif |
| Q39642231 | Regulation of the androgen receptor by SET9-mediated methylation |
| Q44922990 | Regulation of the transcriptional activation of the androgen receptor by the UXT-binding protein VHL. |
| Q35591361 | Reporter Cell Lines for the Characterization of the Interactions between Human Nuclear Receptors and Endocrine Disruptors. |
| Q33960695 | Repression of androgen receptor mediated transcription by the ErbB-3 binding protein, Ebp1. |
| Q35134266 | Research resource: EPSLiM: ensemble predictor for short linear motifs in nuclear hormone receptors. |
| Q33892349 | Roles of steroid receptor coactivator (SRC)-1 and transcriptional intermediary factor (TIF) 2 in androgen receptor activity in mice. |
| Q33955021 | SRY interacts with and negatively regulates androgen receptor transcriptional activity |
| Q30435809 | Simian virus 40 small t antigen mediates conformation-dependent transfer of protein phosphatase 2A onto the androgen receptor |
| Q51636504 | Single-Chain Probes for Illuminating Androgenicity of Chemicals. |
| Q37338900 | Sintokamide A Is a Novel Antagonist of Androgen Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal Domain. |
| Q36777961 | Site-specific androgen receptor serine phosphorylation linked to epidermal growth factor-dependent growth of castration-recurrent prostate cancer |
| Q28910351 | Ski-interacting protein (SKIP) interacts with androgen receptor in the nucleus and modulates androgen-dependent transcription. |
| Q24650935 | Specificity and heregulin regulation of Ebp1 (ErbB3 binding protein 1) mediated repression of androgen receptor signalling |
| Q37145531 | Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance |
| Q39738255 | Structural and functional analysis of amino-terminal enhancer of split in androgen-receptor-driven transcription |
| Q37332443 | Structural and functional characterization of the interdomain interaction in the mineralocorticoid receptor |
| Q34289773 | Structural basis for computational screening of non-steroidal androgen receptor ligands |
| Q43239840 | Structural basis for nuclear receptor corepressor recruitment by antagonist-liganded androgen receptor |
| Q27647445 | Structural characterization of the human androgen receptor ligand-binding domain complexed with EM5744, a rationally designed steroidal ligand bearing a bulky chain directed toward helix 12 |
| Q35417636 | Structural features discriminate androgen receptor N/C terminal and coactivator interactions |
| Q24537137 | Structure and function of steroid receptor AF1 transactivation domains: induction of active conformations |
| Q38838223 | Structures of androgen receptor bound with ligands: advancing understanding of biological functions and drug discovery |
| Q57531405 | Structure–activity relationship studies of miniproteins targeting the androgen receptor–coactivator interaction |
| Q30388743 | Studying Nuclear Receptor Complexes in the Cellular Environment |
| Q24530343 | Supervillin associates with androgen receptor and modulates its transcriptional activity |
| Q38114780 | Targeting alternative sites on the androgen receptor to treat castration-resistant prostate cancer |
| Q40293980 | Targeting the BAF57 SWI/SNF subunit in prostate cancer: a novel platform to control androgen receptor activity |
| Q38212470 | Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects |
| Q28214781 | The FXXLF motif mediates androgen receptor-specific interactions with coregulators |
| Q24292680 | The LATS2/KPM tumor suppressor is a negative regulator of the androgen receptor |
| Q34672872 | The NH(2)-terminal and carboxyl-terminal interaction in the human androgen receptor |
| Q31140532 | The Use of Phage Display Technique for the Isolation of Androgen Receptor Interacting Peptides with (F/W)XXL(F/W) and FXXLY New Signature Motifs |
| Q34772530 | The androgen receptor CAG repeat: a modifier of carcinogenesis? |
| Q38363646 | The androgen receptor interacts with multiple regions of the large subunit of general transcription factor TFIIF. |
| Q33983786 | The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists |
| Q36236084 | The androgen receptor: unlocking the secrets of its unique transactivation domain |
| Q24652993 | The cochaperone Bag-1L enhances androgen receptor action via interaction with the NH2-terminal region of the receptor |
| Q24316455 | The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor |
| Q37590123 | The role of androgen receptor mutations in prostate cancer progression. |
| Q37709925 | The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy |
| Q39336988 | The stress response mediator ATF3 represses androgen signaling by binding the androgen receptor |
| Q24532004 | The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions |
| Q28251356 | Tip110, the human immunodeficiency virus type 1 (HIV-1) Tat-interacting protein of 110 kDa as a negative regulator of androgen receptor (AR) transcriptional activation |
| Q43760059 | Tip60 is a co-activator specific for class I nuclear hormone receptors |
| Q33967239 | Transcriptional synergy between melanoma antigen gene protein-A11 (MAGE-11) and p300 in androgen receptor signaling |
| Q35025253 | Trinucleotide repeat disease. The androgen receptor in spinal and bulbar muscular atrophy |
| Q33837335 | Two panels of steroid receptor luciferase reporter cell lines for compound profiling. |
| Q28216743 | Ubc9 is a novel modulator of the induction properties of glucocorticoid receptors |
| Q37411882 | Understanding nuclear receptor form and function using structural biology |
| Q40563641 | Unique functional properties of a member of the Fushi Tarazu-Factor 1 family from Schistosoma mansoni. |
| Q51263170 | Up-Regulation of Follistatin-Like 1 By the Androgen Receptor and Melanoma Antigen-A11 in Prostate Cancer. |
| Q74568456 | c-Jun potentiates the functional interaction between the amino and carboxyl termini of the androgen receptor |
Search more.